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Introduction: FUS/TLS is an RNA-binding protein whose genetic mutations or pathological inclusions are associated
with neurological diseases including amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration, and
essential tremor (ET). It is unclear whether their pathogenesis is mediated by gain or loss of function of FUS/TLS.
Results: Here, we established outbred FUS/TLS knockout mice to clarify the effects of FUS/TLS dysfunction in vivo.
We obtained homozygous knockout mice that grew into adulthood. Importantly, they did not manifest ALS- or
ET-like phenotypes until nearly two years. Instead, they showed distinct histological and behavioral alterations
including vacuolation in hippocampus, hyperactivity, and reduction in anxiety-like behavior. Knockout mice showed
transcriptome alterations including upregulation of Taf15 and Hnrnpa1, while they have normal morphology of
RNA-related granules such as Gems.
Conclusions: Collectively, FUS/TLS depletion causes phenotypes possibly related to neuropsychiatric and
neurodegenerative conditions, but distinct from ALS and ET, together with specific alterations in RNA metabolisms.
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FUS/TLS is an RNA-binding protein associated with
neurological diseases. Mutations in FUS/TLS cause
familial amyotrophic lateral sclerosis (ALS), in which
FUS/TLS protein is found in cytoplasmic inclusions
[1,2]. In addition, inclusions containing this protein are
also observed in people with sporadic ALS and a subset
of individuals with frontotemporal lobar degeneration
(FTLD) without FUS/TLS mutations [3,4]. More re-
cently, FUS/TLS mutation was found in a family of
hereditary essential tremor (ET) [5]. The pathogenic
mechanisms of these diseases remain unclear. Therefore,
a major research interest is whether FUS/TLS-linked
diseases are caused by gain or loss of function of FUS/* Correspondence: nnukina@juntendo.ac.jp
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unless otherwise stated.TLS. Most FUS/TLS mutations in familial ALS are
thought to disrupt a nuclear localization signal in the
C-terminus, leading to facilitated formation of cytoplas-
mic stress granules as well as reduced nuclear function
[6,7]. Transgenic mice overexpressing FUS/TLS recapitu-
late some ALS-like phenotypes [8]. On the other hand,
reduction in FUS/TLS leads to abnormality in Gems,
nuclear granules marked by SMN1 that is involved in the
assembly of small nuclear ribonucleoprotein particles
and implicated in a motor neuron disease [9,10]. Primary
hippocampal neurons from FUS/TLS-deficient embryos
show abnormal dendritic spines [11]. One critical piece
of information that is still lacking is the phenotype of
adult FUS/TLS knockout (KO) mice, as they die within a
day after birth [12].
FUS/TLS regulates RNA metabolism, which includes
transcription and post-transcriptional processing such as
pre-mRNA splicing and mRNA trafficking, some of
which are related to neuronal functions [13-16]. The
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formation of RNA-containing granules, including neur-
onal granules [17,18]. Moreover, RNA metabolism has
been highlighted as a potential common pathogenic
pathway of ALS/FTLD, because genetic and pathological
abnormalities of another RNA-binding protein, TDP-43,
have been found in these diseases, as with FUS/TLS
[19]. Though previous studies identified transcriptome
changes upon transient depletion of FUS/TLS or those
in FUS/TLS deficient embryos [13-16], the effects of
long-term FUS/TLS depletion on RNA metabolism have
been still unclear.
In this study, we analyzed outbred homozygous FUS/
TLS knockout (KO) mice to clarify the effects of FUS/
TLS depletion on the central nervous system (CNS) in
adults. We found abnormalities of the behavior and




TLS+/- mice [12] were maintained on the C57BL/6 J
(B6) background. To obtain homozygous TLS KO mice,
B6 TLS+/- mice were crossed with ICR mice. The F1
heterozygote mice were intercrossed. To maximize the
survival of KO mice, some of the wild type or heterozy-
gote littermates were removed from the cage. Male mice
were used in experiments. All experiments with mice
were approved by the Animal Experiment Committee of
the RIKEN Brain Science Institute.
Behavioral analysis
The experimental room was maintained in 12 hr light-
12 hr dark periods (light period: 8:00 AM to 8:00 PM).
Animals were tested blindly for their genotypes. For
details of procedures, see Additional file 1: Supplemental
Materials and Methods.
Tremor analysis
A mouse was placed in a plastic box attached with an
accelerometer and allowed to move freely. The motion
of the mouse was recorded for 1-5 minutes at a sam-
pling rate of 1 kHz. Motion power percentage (MPP)
[20] was calculated as (sum of amplitude at 10 ~ 20 Hz)/
(sum of amplitude at 0 ~ 100 Hz) × 100.
Microarray analysis
Three animals were analyzed for each genotype at
8 weeks. 100 ng of total RNA was processed using WT
Expression kit (Ambion) and WT Terminal Labeling kit
(Affymetrix) and subjected to Mouse Exon 1.0 ST array
(Affymetrix) according to the manufacture’s protocol.
Dataset analysis was performed using AltAnalyze [21].Quantitative PCR (qPCR)
Quantitative PCR analysis was performed using Light-
Cycler 480 (Roche) and FastStart Universal SYBR Green
Master (Roche). We used Gapdh for normalization.PCR-based detection of alternative RNA processing
The sequence of primers is listed in Additional file 1:
Supplemental Material. PCR products were resolved by
agarose gel electrophoresis or 5-20% gradient polyacryl-
amide gel electrophoresis and stained with ethidium
bromide or SYBR Gold (Molecular Probe).Results
Absence of ALS- or ET-like phenotypes in outbred
FUS/TLS knockout mice
Consistent with the previous report [12], we could not
obtain homozygous FUS/TLS deficient mice (TLS-/-
mice) on the C57BL/6 J (B6) inbred background due to
their lethality. There was an independent line of TLS-/-
mice that could survive into adulthood on an outbred
background, though their CNS phenotypes were not
analyzed [22]. Thus, we tried to establish TLS-/- mice on
a mixed background of B6 and ICR strains (Figure 1a).
Initially, we obtained TLS-/- pups that survived more
than one day, but with high mortality until weaning
(~80%). In the subsequent cohort, we removed some
TLS+/+ and TLS+/- littermates from newborn TLS-/- pups,
which resulted in the survival of majority of TLS-/- ani-
mals after weaning. Thus, the early postnatal mortality of
outbred TLS-/- mice could be due to competition with
littermates for nutrition rather than to fatal developmen-
tal deficits. The body size of TLS-/- animals was smaller
than that of TLS+/+ and TLS+/- animals (Figure 1b and c).
We confirmed FUS/TLS depletion in TLS-/- mice by
Western blot, quantitative PCR, and immunohistochemi-
cal analyses (Figure 1d-f).
Importantly, the TLS-/- mice did not show apparent
motor deficits, even at 90 weeks of age. The number of
choline acetyltransferase-positive motor neurons in the
spinal cord was not reduced in TLS-/- mice compared to
TLS+/+ mice (Figure 1g and h). Furthermore, muscle
histology of TLS-/- mice did not show apparent atrophic
phenotypes (Figure 1i and j). We also measured tremor-
like movement in TLS-/- mice. In a control experiment,
wild-type mice were treated with harmaline, a widely
used model of essential tremor. They showed a clear
peak of amplitude at 10-18 Hz (Additional file 1: Figure
S1a, Online Resource), reproducing previous results
[20]. In contrast, we did not detect any increase in the
amplitude at this range in TLS-/- mice compared to
TLS+/+ mice (Figure 1k and l). We also tested inbred
TLS+/- mice on the B6 background but again did not
observe tremor-like phenotypes (Additional file 1: Figure
Figure 1 Phenotypes of outbred homozygote FUS/TLS KO mice. (a) PCR genotyping of TLS KO mice. (b) Photograph of TLS+/+ and TLS-/-
mice. (c) Body weight changes of TLS-/- mice. (d) Western blot analysis of TLS protein expression in the striatum of TLS+/+, TLS+/-, and TLS-/- mice
at 8 weeks. Asterisk indicates non-specific cross reactivity of anti-TAF15-M antibody. (e) TLS-M immunoreactivity in the brain sections from TLS+/+
and TLS-/- mice at 8 weeks. Scale bar: 500 μm. (f) qPCR analysis of FUS/TLS mRNA expression in KO mice. The amplicon was located in the 3’UTR
(n = 3). (g, h) Spinal cord sections of 91-week old WT or KO mouse stained with anti-Chat. Scale bar: 10 μm. (i, j) Skeletal muscle sections of
91-week old WT or KO mouse stained with HE. Scale bar: 50 μm. (k) Analysis of tremor-like movements of WT or KO mice at 56 weeks. Amplitude
at each frequency were determined by fast Fourier transformation of records from an accelerometer (n = 13 for WT, n = 15 for KO). (l) Motion
power percentage (MPP; see Additional file 1: Supplemental Materials and Methods) of the range of 10-20 Hz were not elevated in FUS/TLS KO
mice compared to WT mice (n = 13 for WT, n = 15 for KO). P = 0.32 by a two-tailed unpaired t-test. Error bars represent SEM.
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not sufficient for inducing ALS- or ET-like phenotypes
in vivo.Behavioral and histological abnormalities in TLS-/- mice
To characterize TLS-/- mice, we conducted behavioral
analyses. Spontaneous home cage activity was significantly
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dark and light periods (Figure 2a and Additional file 1:
Figure S2a, b, Online Resource). Hyperactivity of KO mice
was also observed in an open field test, as both total
distance moved and average speed of KO mice were
elevated (Figure 2b). The time course revealed that the
locomotive activity of KO mice was indistinguishable from
wild-type mice at the beginning but increased as time
passed (Additional file 1: Figure S2c, Online Resource),
suggesting a habituation-dependent hyperactivity. KO
mice exhibited an increase in time spent on open arms in
an elevated-plus maze test, indicating a reduction in
anxiety-like behavior (Figure 2c). Furthermore, in the
light-dark box test, KO animals took longer before enter-
ing the dark box and spent more time in the light
box, again suggesting reduced anxiety-related behavior
(Figure 2d). An accelerated Rotarod test revealed no
significant difference in motor performance between
WT and KO mice (P = 0.073, Figure 2e). These results
demonstrate that FUS/TLS depletion altered someFigure 2 Behavioral analysis of FUS/TLS KO mice. (a) Spontaneous hom
traveled (arbitrary units) in 7 days is shown. P = 0.0020 (n = 12 for WT, n = 1
movements (P = 0.0045) of WT and KO animals in an open field test at 34 w
animals in an elevated plus maze test at 35 weeks. P = 0.0059 (unpaired tw
WT and KO mice at 41 weeks. Mean ± SEM (n = 13 for WT, n = 21 for KO). K
and longer total time in the light box (P = 0.011), whereas their overall mov
rotarod by WT and KO animals at 39 weeks (P = 0.073, n = 13 for WT, n = 22
significance was evaluated by two-tailed unpaired t-test.aspects of brain function, while motor function of KO
mice was not clearly impaired.
Despite the smaller brain size, the gross structure of
the KO brains looked normal. However, we found
vacuole-like structures in the hippocampal CA3 and
occasionally in the hilus of dentate gyrus of TLS-/- mice
(Figure 3a-c). We observed vacuoles in 6 out of 7 KO
animals but none (0/7) in WT animals at 8-12 weeks old
(P < 0.005, Fisher's exact test). These structures were not
observed at 3 or 4 weeks (Additional file 1: Figure S3a,
Online Resource). Electron microscopy (EM) revealed
that these vacuolar structures contained membranous
and organelle-like components (Figure 3d and e). The
rim of some vacuolar structures was stained with anti-
MAP2, a dendrite marker (Additional file 1: Figure S3b,
Online Resource), but not with other antibodies
examined. We also found a few darkly stained cells
in neuronal cell layers only in TLS-/- mice (Figure 3f ).
Despite these changes, there was no evidence of in-
creased staining of markers for astrocytes and microgliae cage activity of WT and TLS KO mice at 8 weeks. Total distance
1 for KO animals). (b) Total distance (P = 0.0062) and average speed of
eeks (n = 12) (c) Fraction of time spent in open arms by WT and KO
o-tailed t-test, n = 12). (d) Results of a light-dark transition test of TLS
O mice spent longer time before entering into dark box (P = 0.034)
ement was not altered (P = 0.67). (e) Time spent on an accelerating
for KO animals). n.s.: not significant. Error bars represent SEM. Statistical
Figure 3 Histological abnormalities in FUS/TLS KO mice. (a, b) HE-staining of TLS WT and KO mouse sections at 8 weeks of age. Vacuole-like
structures were found in CA3 and the hilus regions of the knockout animal. Scale bar: 500 μm. (c) Magnified image of the vacuolar structures in a
KO animal. Scale bar: 10 μm. (d) Electron microgram of a vacuolar structure in a 12 week-old TLS KO animal. Scale bar: 5 μm. (e) Electron microgram
of the inside of vacuole-like structure in a KO mice. Scale bar: 1 μm. (f) Electron microgram of a dark cell found in a 12 week-old KO animal. Scale
bar: 5 μm. Scale bar: 10 μm.
Kino et al. Acta Neuropathologica Communications  (2015) 3:24 Page 5 of 11(Additional file 1: Figure S3c, Online Resource). Thus,
TLS-/- mice show unconventional pathological abnormal-
ities in the hippocampus. At later stages, hippocampal
vacuolation was observed in 2 out of 3 KO mice at
18 weeks, 1 out of 3 mice at 24 weeks, and 0 out of 3
mice at 47 weeks (Additional file 1: Figure S3d, Online
Resource). Thus, the vacuolation phenotype was not
apparently progressive. Finally, we did not observe
inclusion-like staining of anti-TLS-M in the KO brains at
47 weeks (Additional file 1: Figure S3e, Online Resource).
Gene expression profile of TLS-/- mice
To gain insight into the genes regulated by FUS/TLS
in vivo, we conducted an ExonArray analysis using
samples from TLS+/+ and TLS-/- mice. We tested RNA
samples from striatum and spinal cord at 8 weeks old, at
which point TLS-/- mice showed behavioral (hyperactiv-
ity) and pathological changes (Figures 2 and 3). The
expression of >100 genes was altered in either striatum
or spinal cord of TLS-/- mice, while the number of
overlapping genes in these regions were relatively small
(Figure 4a and Additional file 2: Table S1, Online
Resource). Thus, a large fraction of altered genes by
FUS/TLS depletion were dependent on CNS regions.We did not detect significant enrichment in gene
ontology analysis of these datasets. The results of
selected genes were confirmed using qPCR (Figure 4b
and Additional file 1: Figure S4a, Online Resource).
We observed a strong correlation between microarray
and qPCR results (r = 0.89, Additional file 1: Figure
S5a, see also Additional file 1: Supplemental Materials
and Methods, online resource). To validate the ex-
pression analysis, we also performed qPCR analysis of
additional animal samples that were not used for
microarray analysis and found gene expression changes
consistent with the initial qPCR results (Additional file
1: Figure S5b, Online Resource). Gdpd3, Taf15 and
Hnrnpa1 were commonly upregulated in the striatum
and spinal cord. Taf15 and Ews are homologs of FUS/
TLS. We confirmed that knockdown of FUS/TLS up-
regulated mRNA expression of Taf15 and Ews in
Neuro2a cells (Figure 4c), suggesting a compensatory
regulation within the same protein family. Hnrnpa1 is
an RNA-binding protein recently implicated in ALS
[23]. Protein levels of Taf15, Hnrnpa1 and Ews were
elevated in TLS-/- mice (Figure 1d). We did not ob-
serve significant expression changes of other genes
linked with ALS or FTLD such as Tarbdp, Grn,
Figure 4 RNA expression analysis of FUS/TLS KO mice. (a) Genes up- or down-regulated in the striatum and spinal cord of TLS KO mice
(8 weeks old) detected using ExonArray. (b) qPCR analysis of up- and down-regulated genes in the striatum of TLS KO mice at 8 weeks (n = 3). All
of these genes were significantly down- or up-regulated in the KO mice (p < 0.05, two tailed t-test). (c) qPCR analysis of FUS/TLS family mRNA in
Neuro2A cells depleted of endogenous FUS/TLS using RNAi (n = 4). *P < 0.01, ANOVA followed by Dunnett's test (in comparison with con). Con:
untransfected cells. (d) Types of alternative RNA processing differentially regulated in the striatum of TLS KO mice. (e) Examples of cassette exon
splicing in WT and KO mice. Alternative exons are indicated by red boxes. (f) Examples of alternative terminal exon splicing. Bar charts show qPCR
results using primer sets indicated in the left panels (n = 3). See also Additional file 4: Table S3, online resource.
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showed upregulation of Xlr4b and Xlr3b (Figure 4b
and Additional file 1: Figure S4a, Online Resource),
two related genes implicated in neuronal or behavioral
functions [24,25]. Specifically, overexpression of Xlr4b
was sufficient for inducing abnormal morphology of
dendritic spines [25], a phenotype previously observed
in TLS-/- embryonic neurons [11].
RNA processing and RNA-related granules in TLS-/- mice
We next analyzed RNA processing altered in the TLS-/-
mice. Differentially regulated exons included previously
known and unknown alternative processing (Figure 4d
and Additional file 3: Table S2, Online Resource). We
confirmed selected RNA processing alterations using
gel-based PCR analysis or qPCR (Additional file 4:
Table S3, Online Resource). As examples of differen-
tial cassette exon splicing, we confirmed exon inclu-
sion of Ptk2b, Cnr1, App, Ogdh and Gria1 (Figure 4e
and Additional file 1: Figure S4d, e, Online Resource).
Recent reports suggested that FUS/TLS regulates
alternative splicing of Mapt, encoding tau protein
[26,27,15,14,16]. FUS/TLS-depleted embryonic brains
and primary neurons show elevated inclusion of exon
9, also known as exon 10 in human, related to the
"4-repeat" isoforms. We did not observe alteration in
exon 9 splicing in our KO mice, as this exon was
mostly included even in the WT (Figure 4e). Add-
itionally, we found no significant alteration in the
inclusion of exons 3/4 (Figure 4e). However, we
observed an increase in the inclusion of exon 7B in
KO mice (Figure 4e). This exon consists of 54 nucleo-
tides (Additional file 1: Figure S4f, Online Resource)
and its elevation has been reported in another study
of FUS/TLS depletion in adult mice [15].
Next, we found changes in alternative usage of
terminal exons (Additional file 4: Table S3, Online Re-
source). Differential expression of transcript isoforms
was confirmed for Igbp1, Thra, Enpp5 and Inpp5f
(Figure 4f and Additional file 4: Table S3, Online
Resource). We also detected exons without previous
annotations for RNA processing (Figure 4d). One of
such examples was Gdpd3. We found relative down-
regulation of 5’ regions of Gdpd3 in KO mice com-
pared to the downstream region (Additional file 1:
Figure S4b, Online Resource). 5’-RACE revealed that
the 5’ region of Gdpd3 was shorter in TLS-/- mice
(Additional file 1: Figure S4c, Online Resource),
suggesting a role for FUS/TLS in transcriptional initi-
ation. Collectively, we verified transcriptome changes
in TLS-/- mice, consistent with the role of FUS/TLS
as a regulator of RNA metabolism.
FUS/TLS has been implicated in the formation of
RNA granules and Gems [17,18,10,9]. We observed noovert differences in nuclear SMN1 bodies (Gems) or
cytoplasmic P-bodies in TLS-/- mice (Figure 5a and b),
suggesting that FUS/TLS is dispensable for these struc-
tures. Similarly, staining of stress granule markers as
well as TDP-43 did not reveal differences (Figure 5c-
e). Since FUS/TLS is implicated in mRNA trafficking
[13], we examined protein expression of PSD-95,
FMR1, and Kv1.1, as their transcripts are thought to
be incorporated into neuronal granules and bound by
FUS/TLS [17]. We observed normal expression of
these proteins in TLS-/- mice (Figure 5f and g). Thus,
depletion of FUS/TLS may not globally affect the
integrity of RNA-related granules or the expression of
proteins that are locally translated.
Discussion
Defining FUS/TLS function in vivo is essential not
only for understanding FUS/TLS-associated diseases
but also for designing therapeutic strategies for them.
We generated outbred TLS-/- mice, which grew into
adulthood. In this TLS-/- strain, truncated FUS/TLS
protein has been detected at very low levels in embry-
onic B cells [12]. We did not detect accumulation of
FUS/TLS in TLS-/- mice at 8 and 47 weeks, at the
stages when they show phenotypical changes. Consid-
ering the aggregation-prone property of FUS/TLS lack-
ing the C-terminus [28], the absence of pathological
accumulation of FUS/TLS indicates that the protein
expression from the mutant allele was too low to
accumulate and supports that the phenotype of TLS-/-
mice are mainly attributed to the loss of full-length
FUS/TLS protein. Our mice provided several import-
ant findings summarized as follows.
(1) KO mice did not show ALS- or ET-like symptoms.
The simplest interpretation is that loss of FUS/TLS
function is not sufficient to cause ALS or ET, suggesting
that FUS/TLS mutations in these diseases must involve
some adverse effects distinct from simple loss of func-
tion. In line with this, transgenic mice overexpressing
wild type FUS/TLS or its N-terminal fragment manifest
ALS-like phenotypes together with pathological inclu-
sions [8,28]. We do not rule out the possibility that loss
of function of FUS/TLS causes ALS or ET depending on
the genetic background or the timing of FUS/TLS deple-
tion. If this is the case, however, our results would pro-
vide a therapeutic implication that ALS or ET caused by
FUS/TLS depletion can be fully prevented by some gen-
etic factors or compensatory responses, perhaps includ-
ing upregulation of Taf15 and Ews. It is also possible that
these disease are caused by the combinatorial effects of
both gain and loss of function of FUS/TLS. (2) KO mice
showed behavioral abnormalities, namely hyperactivity
and reduced anxiety-related behavior, both of which were
supported by multiple different tests. The hyperactivity of
Figure 5 Protein expression analysis of FUS/TLS KO mice. (a) Staining of nuclear SMN1 granules (Gems) in the hippocampal CA3 regions of
WT and KO mice at 8 weeks. Number of Gems was not altered in KO mice (P = 0.49, n = 3, t-test). (b) Staining of Rck/Ddx6, a marker of P-body
(scale bar: 10 μm). (c, d) Immunostaining of stress granules markers (TIAR in c and eIF3eta in d) in the CA3 region. (e) TDP-43 staining in the CA3
region (scale bar 10 μm). (f) Staining of PSD-95 in the hippocampus (scale bar: 500 μm), FMR1 and Kv1.1 in the CA1 region (scale bar: 10 μm).
(g) Protein expression analysis of total lysates from the hippocampus of FUS/TLS knockout mice at 8 weeks.
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type observed in human attention deficit/hyperactivity
disorder (ADHD) [29]. FUS/TLS is located in a region
(16p11.2), where genomic copy number variations were
found in ADHD individuals [30]. (3) We also observed
vacuole-like structures in the hippocampus of KO mice.
Though vacuolation is known in some disease condi-
tions represented by prion diseases, the underlyingmechanisms are unclear. As the rim of vacuoles was
stained with anti-MAP2, they might originate from
dendrites or related structures. There are several genes
whose mutation is associated with hippocampal vacuol-
ation in mice (Prnp, Atrn, Mgrn1, Sp4, Gja1, Gjb6,
Pnpla6), however, none of them showed altered mRNA
expression in FUS/TLS KO mice. Therefore, FUS/TLS
might be involved in a novel molecular pathway of
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susceptible to FUS/TLS depletion. Though hippocam-
pal vacuolation is not a typical pathological feature of
FTLD, loss of FUS/TLS function might contribute to
the abnormalities in FLTD hippocampus. In this re-
gard, it is notable that FUS/TLS-positive inclusions in
FTLD, but not those in ALS-FUS, are also positive for
TAF15 and EWS [31], suggesting composite defects of
the FUS/EWS/TAF15 protein family in FTLD-FUS that
preclude functional compensation within the family.
We noticed that the vacuolation was less frequent at
later stages. At present, it is unclear whether the
reduced frequency reflected recovery of the phenotype.
Interestingly, there is an example of transient CA3
vacuolation, which was induced by Sp4 deficiency [32].
The transcriptome changes detected in our animals
are important because some of these changes might be
causally or consequentially related to the behavioral and
pathological phenotypes. We found that adult TLS-/-
mice show alterations in both gene expression and RNA
processing, some of which were also identified previ-
ously and may represent reliable targets of FUS/TLS
(Additional file 5: Table S4, Online Resource). We
observed relatively small overlap of genes whose ex-
pression levels were altered in CNS regions analyzed
(Figure 4a). Consistently, primary neurons from differ-
ent CNS regions and glial cells show differential
changes in their transcriptome when FUS/TLS is
depleted [33]. While reduction of Gems was reported
in embryonic neurons from an independent strain of
FUS/TLS KO mice [9], we observed a normal appear-
ance of Gems. This discrepancy might be due to the
cell types, conditions including genetic backgrounds,
design of the mutant alleles, developmental stages, and
the time span of FUS/TLS depletion in each study. We do
not exclude the possibility that the trace amount of
truncated FUS/TLS from the mutant allele in our mice
prevented the abnormalities of Gems and some other
RNA processing, which led to the viability of these mice.
In any case, our results indicate that FUS/TLS may not be
absolutely required for Gems. In this way, our mice
provide unique opportunities to reveal the long-term
effects of FUS/TLS depletion in adults.
Conclusion
In conclusion, our results demonstrate that deficiency of
FUS/TLS leads to behavioral and pathological abnormalities
that might be relevant to neuropsychiatric or neurodegen-
erative disorders, including FTLD. However, FUS/TLS KO
mice did not develop phenotypes similar to ALS or ET.
We also identified transcriptome changes caused by FUS/
TLS depletion, which would be useful for future identifi-
cation of biomarkers as well as molecular pathways
reflecting FUS/TLS dysfunction in vivo.Availability of supporting data
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